We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

A breakthrough in our understanding of mRNA delivery systems in the body may allow for more direct treatments for ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

An mRNA cancer vaccine triggered strong immune responses and improved treatment outcomes in mice, offering a new approach to ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and ...

What if mRNA vaccines could be made more powerful and less irritating? Scientists at the University of Pennsylvania have ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

Indeed, mRNA vaccines designed to treat cancer (among other diseases) “are quite realistic,” says Anna Blakney, an RNA researcher at the University of British Columbia.